•   
  •   
  •   

Health & Fit AstraZeneca's COVID-19 vaccine produces an immune response in older people, raising hopes a vaccine will protect those at greatest risk

08:25  27 october  2020
08:25  27 october  2020 Source:   businessinsider.com

Why the AstraZeneca-Oxford Covid-19 vaccine is different

  Why the AstraZeneca-Oxford Covid-19 vaccine is different AstraZeneca and the University of Oxford say their vaccine is up to 90 percent effective. But there’s a lot we still don’t know.Yet with Monday’s news from AstraZeneca and University of Oxford that early results from their phase 3 trial demonstrate their vaccine’s effectiveness, that’s exactly the scenario we’re in.

AstraZeneca ' s COVID - 19 vaccine produces an immune response in elderly people , the drugmaker said on Monday. This does not necessarily mean the vaccine , being developed alongside the University of Oxford, is safe and effective in older people — but it is promising news, given that the

Interim results suggest AstraZeneca ' s vaccine with the University of Oxford prompts an immune response in both older and younger adults. AstraZeneca said on Monday that its experimental COVID - 19 vaccine had produced an immune response in both older adults, the age group at

a man and a woman taking a selfie: Dr. Mustafa Gerek is vaccinated in volunteer in trials of a COVID-19 vaccine from China at Ankara City Hospital in Ankara, Turkey on October 13, 2020. Aytac Unal/Anadolu Agency via Getty Images © Aytac Unal/Anadolu Agency via Getty Images Dr. Mustafa Gerek is vaccinated in volunteer in trials of a COVID-19 vaccine from China at Ankara City Hospital in Ankara, Turkey on October 13, 2020. Aytac Unal/Anadolu Agency via Getty Images
  • AstraZeneca's COVID-19 vaccine triggers an immune response in elderly people as well as young adults, the drugmaker said Monday.
  • "Immunogenicity responses were similar between older and younger adults," an AstraZeneca spokesperson said.
  • The vaccine, being developed with the University of Oxford, is one of the world's leading COVID-19 vaccine candidates.
  • This does not necessarily mean the vaccine is safe and effective — but it is promising news, given that the immune system weakens as a person grows older.
  • Visit Business Insider's homepage for more stories.

AstraZeneca's COVID-19 vaccine produces an immune response in elderly people, the drugmaker said on Monday.

Internal AstraZeneca safety report sheds light on neurological condition suffered by vaccine trial participant

  Internal AstraZeneca safety report sheds light on neurological condition suffered by vaccine trial participant CNN has obtained an internal safety report by pharmaceutical giant AstraZeneca that sheds light on the neurological condition suffered by one of the participants in its coronavirus vaccine clinical trial. © Jason Alden/Bloomberg/Getty Images A sign featuring the AstraZeneca Plc logo stands at the company's DaVinci building at the Melbourn Science Park in Cambridge, U.K., on Monday, June 8, 2020. AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.

AstraZeneca said Monday (October 26) that a coronavirus vaccine it is developing with the University of Oxford produces an immune response in both the elderly and the young. The UK drugmaker also said that adverse reactions were lower among the elderly. Britain' s Financial Times newspaper

A vaccine that works is seen as a game-changer in the battle against Covid - 19 , which has killed more than 1.15 million worldwide. Photo: AP. One of the world’ s leading Covid - 19 experimental vaccines produces a immune response in both young and old adults, raising hopes of a path out of the

This does not necessarily mean the vaccine, being developed alongside the University of Oxford, is safe and effective in older people — but it is promising news, given that the immune system weakens as a person grows older.

AstraZeneca also said "reactogenicity" — expected adverse reactions to the virus, which commonly include sore arm or swelling — was lower in older people than younger people.

An AstraZeneca spokesperson told Business Insider: "It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher."

"The results further build the body of evidence for the safety and immunogenicity of AZD1222," the name of the vaccine, the spokesperson added.

If You're This Old, You May Be Last to Get the COVID Vaccine, Fauci Says

  If You're This Old, You May Be Last to Get the COVID Vaccine, Fauci Says According to Dr. Anthony Fauci, the last group to be vaccinated against coronavrius (COVID-19) will likely be children.Fauci revealed in a recent interview with Andrea Mitchell of MSNBC that higher risk populations — older adults and anyone else who is considered high risk — will have first dibs on the vaccine. As for everyone else — the "general population" they will have to wait a few months, likely until late April or early May. "As you go down the list, it gets to people who are less at risk for serious disease," will be at the back end, Fauci said on NPR.

British pharmaceutical giant AstraZeneca said its Covid - 19 vaccine candidate has produced a similar immune response in older and younger adults. AstraZeneca CEO Pascal Soirot has previously said the drugmaker' s vaccine would likely provide protection against contracting the coronavirus for

drugmaker AstraZeneca announced that their experimental COVID - 19 vaccine produces a similar immune response in both older and younger adults. The current University of Oxford vaccine , also known as, AZD1222, is considered a frontrunner in the race to protect people around the world from


Video: Vaccine produces immune response - AstraZeneca (Reuters)

The drugmakers' statement Monday came after the the Financial Times reported that the vaccine, one of the world's leading candidates, triggers protective antibodies and T-cells in older people, citing two people familiar with trial data.

The findings came from blood tests carried out on a subset of older participants in the vaccine trials. Details of the results are expected to be published in a clinical journal, the FT said.

These results compare to data released in July that showed the vaccine produced immune responses in a group of healthy adults between the ages of 18 and 55, the FT reported.

The findings come after the Food and Drug Administration allowed AstraZeneca on Friday to resume its vaccine trials in the US after a participant reported a "severe adverse reaction" on September 6.

Moderna Announces Vaccine Nearly 95% Effective

  Moderna Announces Vaccine Nearly 95% Effective “This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Moderna CEO Stephane Bancel said in a statement. "Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease." Read on to hear when you might get yours, and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.

Oxford coronavirus vaccine seems to produce an immune response in people over 55. COVID - 19 : The Pandemic that Never Should Have Happened, and How to Stop the Next One by Debora Transfusions of plasma from people who have recovered from covid - 19 offer limited benefit in terms

A promising coronavirus vaccine being developed by the University of Oxford produces an immune response in both elderly and young people , British drugmaker AstraZeneca said on Monday.

Coronavirus has killed more than 1.15 million people worldwide.

With dozens of vaccine candidates in late-stage clinical trials, including AstraZeneca's, hope remains that a safe, effective vaccine will be developed before the end of the year.

White House coronavirus advisor Dr. Anthony Fauci said in a BBC interview on Sunday: "We will know whether a vaccine is safe and effective by the end of November, the beginning of December."

Fauci added: "The question is: Once you have a safe and effective vaccine, or more than one, how can you get it to the people who need it as quickly as possible?"

Read the original article on Business Insider

Dr. Fauci Says This "Innocent" Activity Could Get You Killed .
Dr. Fauci worries that Thanksgiving travel will cause a surge of coronavirus (COVID-19) cases that might overwhelm hospitals. "When you think of the holiday season and the congregating indoors at what are innocent, lovely functions like meals with family and friends, you've got to really think" of the risk factors, said Fauci.

usr: 4
This is interesting!